Patents by Inventor Sebastien Jauliac

Sebastien Jauliac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MIRNA COMPOSITION COMPRISING 11 SPECIFIC MIRNAS AND ITS USE IN THE TREATMENT OF CANCER
    Publication number: 20240084300
    Abstract: The present invention relates to a miRNA composition comprising the following 11 miRNAs: hsa-miR-3195, hsa-miR-1246, hsa-miR-188-3p, hsa-miR-16-5p, hsa-miR-196a-3p, hsa-miR-32-5p, hsa-miR-4532, hsa-miR-4792, hsa-miR-4488, hsa-miR-326, and hsa-miR-7704. Optionally, it may further comprise at least one miRNA selected from hsa-miR-195-5p, hsa-miR-324-3p, hsa-miR-4449 and hsa-miR-501-5p. It further relates to liposomes or SEVs loaded by said miRNA composition, to methods for preparing the loaded SEVs, to a pharmaceutical composition comprising the miRNA composition, liposomes or SEVs, and to therapeutic uses of the pharmaceutical composition, in particular in the treatment of cancer.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventor: Sébastien JAULIAC
  • Compositions comprising secreted extracellular vesicles of cells expressing NFATC4 useful for the treatment of cancer
    Patent number: 11154598
    Abstract: The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGF?1 expression level.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 26, 2021
    Assignees: Université de Paris, Institut National de la Sante et de la Recherce Medicale, Assistance Publique—Hopitaux de Paris
    Inventors: Sébastien Jauliac, Livia Camargo
  • COMPOSITIONS COMPRISING SECRETED EXTRACELLULAR VESICLES OF CELLS EXPRESSING NFATC4 USEFUL FOR THE TREATMENT OF CANCER
    Publication number: 20190117688
    Abstract: The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGF?1 expression level.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 25, 2019
    Applicants: Universite Paris Diderot Paris 7, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique - Hopitaux de Paris
    Inventors: Sébastien Jauliac, Livia Camargo
  • NFAT transcription factors in tumor progression
    Publication number: 20050100897
    Abstract: The present invention provides therapeutic and diagnositic methods for neoplasia treatment. The invention also relates to determining the prognosis of a neoplasia or determining a treatment protocal. Further features of the invention are methods for identifying NFAT target genes that promote neoplasia progression.
    Type: Application
    Filed: March 31, 2003
    Publication date: May 12, 2005
    Inventors: Alex Toker, Sebastien Jauliac